{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:27:19Z","timestamp":1791239239093,"version":"4.1.0"},"reference-count":246,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10787-026-02341-z","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:48:08Z","timestamp":1787384888000},"page":"6003-6034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Thumbar Kishan","family":"Dineshbhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhvani","family":"Rafaliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6130","authenticated-orcid":false,"given":"Aditya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-4229","authenticated-orcid":false,"given":"Shubhrat","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-1851","authenticated-orcid":false,"given":"Manisha","family":"Lalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-0486","authenticated-orcid":false,"given":"Guno Sindhu","family":"Chakraborthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"3","key":"2341_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/ijms22031231","volume":"22","author":"IM Abdallah","year":"2021","unstructured":"Abdallah IM, Al-Shami KM, Yang E, Kaddoumi A (2021) Blood-brain barrier disruption increases amyloid-related pathology in TgSwDI mice. Int J Mol Sci 22(3):1231","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2341_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13195-024-01537-1","volume":"16","author":"N Abdulhameed","year":"2024","unstructured":"Abdulhameed N, Babin A, Hansen K, Weaver R, Banks WA, Talbot K et al (2024) Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP\/PS1 mouse model of Alzheimer\u2019s disease. Alzheimers Res Ther 16(1):173. https:\/\/doi.org\/10.1186\/s13195-024-01537-1","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2341_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08186-8","volume":"17","author":"AA Abdulkhaliq","year":"2026","unstructured":"Abdulkhaliq AA, Kim B, Almoghrabi YM, Khan J, Ajoolabady A, Ren J et al (2026) Amyloid-\u03b2 and Tau in Alzheimer\u2019s disease: pathogenesis, mechanisms, and interplay. Cell Death Dis 17(1):21","journal-title":"Cell Death Dis"},{"issue":"4","key":"2341_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/nu13041383","volume":"13","author":"A Al Mansoori","year":"2021","unstructured":"Al Mansoori A, Shakoor H, Ali HI, Feehan J, Al Dhaheri AS, Cheikh Ismail L et al (2021) The effects of bariatric surgery on vitamin B status and mental health. Nutrients 13(4):1383","journal-title":"Nutrients"},{"key":"2341_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6564585","author":"A Alahmari","year":"2021","unstructured":"Alahmari A (2021) Blood-brain barrier overview: structural and functional correlation. Neural Plast https:\/\/doi.org\/10.1155\/2021\/6564585","journal-title":"Neural Plast"},{"key":"2341_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neures.2023.02.001","volume":"197","author":"M Albini","year":"2023","unstructured":"Albini M, Krawczun-Rygmaczewska A, Cesca F (2023) Astrocytes and brain-derived neurotrophic factor (BDNF). Neurosci Res 197:42\u201351","journal-title":"Neurosci Res"},{"key":"2341_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251343296","author":"ZS Alexopoulou","year":"2025","unstructured":"Alexopoulou ZS, K\u00f6hler S, Mallick E, Tr\u00f6ger J, Linz N, Spruth E et al (2025) Speech-based digital cognitive assessments for detection of mild cognitive impairment: validation against paper-based neurocognitive assessment scores. J Alzheimer\u2019s Dis. https:\/\/doi.org\/10.1177\/13872877251343296","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2341_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","volume":"71","author":"T Alqahtani","year":"2023","unstructured":"Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Dadarao Chakole R et al (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and Amyotrophic Lateral Sclerosis -An updated review. Mitochondrion 71:83\u201392","journal-title":"Mitochondrion"},{"issue":"7","key":"2341_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14856","volume":"30","author":"M AmeliMojarad","year":"2024","unstructured":"AmeliMojarad M, AmeliMojarad M (2024) The neuroinflammatory role of microglia in Alzheimer\u2019s disease and their associated therapeutic targets. CNS Neurosci Ther 30(7):e14856. https:\/\/doi.org\/10.1111\/cns.14856","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"2341_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1134\/S1819712423020034","volume":"17","author":"EA Anderzhanova","year":"2023","unstructured":"Anderzhanova EA, Voronina TA (2023) Irisin at the croasroad of autophagy and BNDF signaling for neuroplasticity regulation. Neurochem J 17(2):189\u2013201. https:\/\/doi.org\/10.1134\/S1819712423020034","journal-title":"Neurochem J"},{"key":"2341_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122167","volume":"626","author":"S Andrade","year":"2022","unstructured":"Andrade S, Ramalho MJ, Loureiro JA, Pereira MC (2022) Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer\u2019s disease therapy. Int J Pharm 626:122167","journal-title":"Int J Pharm"},{"key":"2341_CR12","doi-asserted-by":"publisher","DOI":"10.2174\/0122117385335626241204165702","author":"SA Ansari","year":"2024","unstructured":"Ansari SA, Alshanberi AM, Satar R, Abujamai J, Ashraf GM (2024) Current updates on nanotechnology-based drug delivery platforms for treating Alzheimer\u2019s with herbal drugs. Pharm Nanotechnol. https:\/\/doi.org\/10.2174\/0122117385335626241204165702","journal-title":"Pharm Nanotechnol"},{"issue":"2","key":"2341_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1021\/acs.molpharmaceut.0c00461","volume":"18","author":"S Arora","year":"2021","unstructured":"Arora S, Layek B, Singh J (2021) Design and validation of liposomal ApoE2 gene delivery system to evade blood\u2013brain barrier for effective treatment of Alzheimer\u2019s disease. Mol Pharm 18(2):714\u2013725. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00461","journal-title":"Mol Pharm"},{"issue":"5","key":"2341_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2341_CR15","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig\u2010Pijoan A, Mil\u00e0\u2010Alom\u00e0 M, Fern\u00e1ndez\u2010Lebrero A, Garc\u00eda\u2010Escobar G, Gonz\u00e1lez\u2010Ortiz F et al (2023) Plasma and CSF biomarkers in a memory clinic: head\u2010to\u2010head comparison of phosphorylated tau immunoassays. Alzheimers Dement 19(5):1913\u20131924. https:\/\/doi.org\/10.1002\/alz.12841","journal-title":"Alzheimers Dement"},{"key":"2341_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103932","volume":"78","author":"S Bahadur","year":"2022","unstructured":"Bahadur S, Jha MK (2022) Emerging nanoformulations for drug targeting to brain through intranasal delivery: a comprehensive review. J Drug Deliv Sci Technol 78:103932","journal-title":"J Drug Deliv Sci Technol"},{"issue":"11\u201312","key":"2341_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.18071\/isz.74.0379","volume":"74","author":"N Bal\u00e1zs","year":"2021","unstructured":"Bal\u00e1zs N, Bereczki D, Kov\u00e1cs T (2021) Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias. Ideggyogy Sz 74(11\u201312):379\u2013387","journal-title":"Ideggyogy Sz"},{"key":"2341_CR18","doi-asserted-by":"publisher","first-page":"123937","DOI":"10.1016\/j.lfs.2025.123937","volume":"380","author":"KC Basavaraju","year":"2025","unstructured":"Basavaraju KC, Priyadarshini P (2025) From synaptic dynamics to cognitive decline: molecular insights into neuroplasticity. Life Sci 380:123937","journal-title":"Life Sci"},{"issue":"1","key":"2341_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM et al (2021) Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther 13(1):198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2341_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3233\/ADR-220112","volume":"7","author":"A Behera","year":"2023","unstructured":"Behera A, Sa N, Pradhan SP, Swain S, Sahu PK (2023) Metal nanoparticles in Alzheimer\u2019s disease. J Alzheimers Dis Rep 7(1):791\u2013810. https:\/\/doi.org\/10.3233\/ADR-220112","journal-title":"J Alzheimers Dis Rep"},{"key":"2341_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102556","volume":"102","author":"T Behl","year":"2024","unstructured":"Behl T, Kyada A, Roopashree R, Nathiya D, Arya R, Kumar MR et al (2024) Epigenetic biomarkers in Alzheimer\u2019s disease: diagnostic and prognostic relevance. Ageing Res Rev 102:102556","journal-title":"Ageing Res Rev"},{"issue":"3","key":"2341_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3233\/JAD-201077","volume":"79","author":"MJ Ben\u00edtez","year":"2021","unstructured":"Ben\u00edtez MJ, Cuadros R, Jim\u00e9nez JS (2021) Phosphorylation and dephosphorylation of Tau protein by the catalytic subunit of PKA, as probed by electrophoretic mobility retard. J Alzheimers Dis 79(3):1143\u20131156. https:\/\/doi.org\/10.3233\/JAD-201077","journal-title":"J Alzheimers Dis"},{"key":"2341_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105192","volume":"150","author":"AS Berry","year":"2023","unstructured":"Berry AS, Harrison TM (2023) New perspectives on the basal forebrain cholinergic system in Alzheimer\u2019s disease. Neurosci Biobehav Rev 150:105192","journal-title":"Neurosci Biobehav Rev"},{"issue":"41","key":"2341_CR24","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1523\/JNEUROSCI.0379-23.2023","volume":"43","author":"N Bhembre","year":"2023","unstructured":"Bhembre N, Bonthron C, Opazo P (2023) Synaptic compensatory plasticity in Alzheimer\u2019s disease. J Neurosci 43(41):6833\u20136840","journal-title":"J Neurosci"},{"key":"2341_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-026-00934-4","author":"PJ Bice","year":"2026","unstructured":"Bice PJ, Nho K, Ertekin-Taner N, Saykin AJ (2026) Systems biology of Alzheimer\u2019s disease: a scoping review of key pathways and mechanisms. Mol Neurodegener https:\/\/doi.org\/10.1186\/s13024-026-00934-4","journal-title":"Mol Neurodegener"},{"key":"2341_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113112","volume":"324","author":"AC Boese","year":"2020","unstructured":"Boese AC, Hamblin MH, Lee JP (2020) Neural stem cell therapy for neurovascular injury in Alzheimer\u2019s disease. Exp Neurol 324:113112","journal-title":"Exp Neurol"},{"issue":"16","key":"2341_CR28","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3390\/jcm13164661","volume":"13","author":"A Bougea","year":"2024","unstructured":"Bougea A, Gourzis P (2024) Biomarker-based precision therapy for Alzheimer\u2019s disease: multidimensional evidence leading a new breakthrough in personalized medicine. J Clin Med 13(16):4661","journal-title":"J Clin Med"},{"issue":"3","key":"2341_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neumar.2025.100107","volume":"2","author":"J Braudeau","year":"2025","unstructured":"Braudeau J, Souchet B, Streel E (2025) Optimizing Alzheimer\u2019s diagnosis and precision medicine: a narrative review unlocking the potential of multiomics markers. NeuroMarkers 2(3):100107","journal-title":"NeuroMarkers"},{"issue":"1","key":"2341_CR30","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai H, Pang Y, Fu X, Ren Z, Jia L (2023) Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts. Nat Commun 14(1):6747","journal-title":"Nat Commun"},{"issue":"12","key":"2341_CR31","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1038\/s41380-023-02140-w","volume":"28","author":"G Carello-Collar","year":"2023","unstructured":"Carello-Collar G, Bellaver B, Ferreira PCL, Ferrari-Souza JP, Ramos VG, Therriault J et al (2023) The GABAergic system in Alzheimer\u2019s disease: a systematic review with meta-analysis. Mol Psychiatry 28(12):5025\u20135036","journal-title":"Mol Psychiatry"},{"issue":"9","key":"2341_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11091631","volume":"11","author":"A Carocci","year":"2022","unstructured":"Carocci A, Barbarossa A, Leuci R, Carrieri A, Brunetti L, Laghezza A et al (2022) Novel phenothiazine\/donepezil-like hybrids endowed with antioxidant activity for a multi-target approach to the therapy of Alzheimer\u2019s disease. Antioxidants (Basel) 11(9):1631","journal-title":"Antioxidants (Basel)"},{"key":"2341_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2022.08.008","volume":"86","author":"S Chaturvedi","year":"2022","unstructured":"Chaturvedi S, Naseem Z, El-Khamisy SF, Wahajuddin M (2022) Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence. Semin Cancer Biol 86:46\u201353","journal-title":"Semin Cancer Biol"},{"key":"2341_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.631827\/full","volume":"13","author":"Y Chen","year":"2021","unstructured":"Chen Y, Hong T, Chen F, Sun Y, Wang Y, Cui L (2021) Interplay between Microglia and Alzheimer\u2019s disease\u2014focus on the most relevant risks: APOE genotype, sex and age. Front Aging Neurosci 13:631827. https:\/\/doi.org\/10.3389\/fnagi.2021.631827\/full","journal-title":"Front Aging Neurosci"},{"key":"2341_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jconrel.2024.07.010","volume":"373","author":"Y Chen","year":"2024","unstructured":"Chen Y, Huang L, Luo Z, Han D, Luo W, Wan R et al (2024) Pantothenate-encapsulated liposomes combined with exercise for effective inhibition of CRM1-mediated PKM2 translocation in Alzheimer\u2019s therapy. J Control Release 373:336\u2013357","journal-title":"J Control Release"},{"key":"2341_CR36","doi-asserted-by":"publisher","first-page":"1258640","DOI":"10.3389\/fnagi.2023.1258640\/full","volume":"15","author":"Y Chen","year":"2023","unstructured":"Chen Y, He Y, Han J, Wei W, Chen F (2023) Blood-brain barrier dysfunction and Alzheimer\u2019s disease: associations, pathogenic mechanisms, and therapeutic potential. Front Aging Neurosci 15:1258640. https:\/\/doi.org\/10.3389\/fnagi.2023.1258640\/full","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2341_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-00195-1","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Tian DY, Wang YJ (2020) Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives. Transl Neurodegener 9(1):16. https:\/\/doi.org\/10.1186\/s40035-020-00195-1","journal-title":"Transl Neurodegener"},{"issue":"8","key":"2341_CR38","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1080\/09638288.2022.2060334","volume":"45","author":"EC Chiu","year":"2023","unstructured":"Chiu EC, Wang YC, Huang SL, Hsueh IP, Chiang H, Hsieh CL (2023) Test\u2013retest reliabilities and minimal detectable changes of 5 versions of the Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale in people with dementia. Disabil Rehabil 45(8):1398\u20131404. https:\/\/doi.org\/10.1080\/09638288.2022.2060334","journal-title":"Disabil Rehabil"},{"issue":"12","key":"2341_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19(12):715\u2013736","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2341_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/alz.12612","volume":"19","author":"K Connolly","year":"2023","unstructured":"Connolly K, Lehoux M, O\u2019Rourke R, Assetta B, Erdemir GA, Elias JA et al (2023) Potential role of chitinase-3-like protein 1 (CHI3L1\/YKL-40) in neurodegeneration and Alzheimer\u2019s disease. Alzheimer\u2019s Dement 19(1):9\u201324. https:\/\/doi.org\/10.1002\/alz.12612","journal-title":"Alzheimer\u2019s Dement"},{"key":"2341_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F (2023) Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement Transl Res Clin Interv. https:\/\/doi.org\/10.1002\/trc2.12385","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"6","key":"2341_CR42","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","volume":"181","author":"A Deczkowska","year":"2020","unstructured":"Deczkowska A, Weiner A, Amit I (2020) The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181(6):1207\u20131217","journal-title":"Cell"},{"issue":"1","key":"2341_CR43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12035-021-02612-6","volume":"59","author":"R Dhapola","year":"2022","unstructured":"Dhapola R, Sarma P, Medhi B, Prakash A, Reddy DH (2022) Recent advances in molecular pathways and therapeutic implications targeting mitochondrial dysfunction for Alzheimer\u2019s disease. Mol Neurobiol 59(1):535\u2013555. https:\/\/doi.org\/10.1007\/s12035-021-02612-6","journal-title":"Mol Neurobiol"},{"issue":"12","key":"2341_CR44","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Aducanumab: first approval. Drugs 81(12):1437\u20131443. https:\/\/doi.org\/10.1007\/s40265-021-01569-z","journal-title":"Drugs"},{"issue":"1","key":"2341_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/pharmaceutics16010058","volume":"16","author":"S Dighe","year":"2023","unstructured":"Dighe S, Jog S, Momin M, Sawarkar S, Omri A (2023) Intranasal drug delivery by nanotechnology: advances in and challenges for Alzheimer\u2019s disease management. Pharmaceutics 16(1):58","journal-title":"Pharmaceutics"},{"key":"2341_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105783","volume":"171","author":"XW Ding","year":"2021","unstructured":"Ding XW, Robinson M, Li R, Aldhowayan H, Geetha T, Babu JR (2021) Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in diabetes mellitus and Alzheimer\u2019s disease. Pharmacol Res 171:105783","journal-title":"Pharmacol Res"},{"key":"2341_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2022.05.056","volume":"348","author":"H Ding","year":"2022","unstructured":"Ding H, Tan P, Fu S, Tian X, Zhang H, Ma X et al (2022) Preparation and application of pH-responsive drug delivery systems. J Control Release 348:206\u2013238","journal-title":"J Control Release"},{"issue":"12","key":"2341_CR48","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1002\/alz.13428","volume":"19","author":"T Doherty","year":"2023","unstructured":"Doherty T, Yao Z, Khleifat AAl, Tantiangco H, Tamburin S, Albertyn C et al (2023) Artificial intelligence for dementia drug discovery and trials optimization. Alzheimers Dement 19(12):5922\u20135933. https:\/\/doi.org\/10.1002\/alz.13428","journal-title":"Alzheimers Dement"},{"key":"2341_CR49","doi-asserted-by":"publisher","first-page":"1432002","DOI":"10.3389\/fncel.2024.1432002\/full","volume":"18","author":"SSK Durairajan","year":"2024","unstructured":"Durairajan SSK, Selvarasu K, Singh AK, Patnaik S, Iyaswamy A, Jaiswal Y et al (2024) Unraveling the interplay of kinesin-1, tau, and microtubules in neurodegeneration associated with Alzheimer\u2019s disease. Front Cell Neurosci 18:1432002. https:\/\/doi.org\/10.3389\/fncel.2024.1432002\/full","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"2341_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-025-02432-6","volume":"75","author":"N Ebadpour","year":"2025","unstructured":"Ebadpour N, Abavisani M, Karav S, Kesharwani P, Sahebkar A (2025) Exosome\/extracellular vesicles-based therapeutics in Alzheimer\u2019s disease: neuroprotective roles and future perspectives. J Mol Neurosci 75(4):137. https:\/\/doi.org\/10.1007\/s12031-025-02432-6","journal-title":"J Mol Neurosci"},{"issue":"7","key":"2341_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-025-01712-9","volume":"40","author":"R Ebrahimi","year":"2025","unstructured":"Ebrahimi R, Golzari Z, Heidari-Foroozan M, Khosravi A, Ghaheri Sharghi S, Saleh M et al (2025) Impaired synaptic plasticity mechanisms in Alzheimer\u2019s disease. Metab Brain Dis 40(7):277. https:\/\/doi.org\/10.1007\/s11011-025-01712-9","journal-title":"Metab Brain Dis"},{"issue":"1","key":"2341_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamaneurol.2024.3533","volume":"82","author":"CM Erickson","year":"2025","unstructured":"Erickson CM, Wexler A, Largent EA (2025) Digital biomarkers for neurodegenerative disease. JAMA Neurol 82(1):5","journal-title":"JAMA Neurol"},{"issue":"11","key":"2341_CR53","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1007\/s00210-024-03188-3","volume":"397","author":"SM Firdous","year":"2024","unstructured":"Firdous SM, Khan SA, Maity A (2024) Oxidative stress\u2013mediated neuroinflammation in Alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 397(11):8189\u20138209. https:\/\/doi.org\/10.1007\/s00210-024-03188-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"2341_CR54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14737175.2025.2527211","volume":"25","author":"J Fortea","year":"2025","unstructured":"Fortea J, Ferrer-Pic\u00f3n E (2025) An overview of the rivastigmine 13.3 mg\/24h transdermal patch as a treatment option for Alzheimer\u2019s disease. Expert Rev Neurother 25(9):1119\u20131129. https:\/\/doi.org\/10.1080\/14737175.2025.2527211","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"2341_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41467-019-14159-1","volume":"11","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R et al (2020) Functional brain architecture is associated with the rate of tau accumulation in Alzheimer\u2019s disease. Nat Commun 11(1):347","journal-title":"Nat Commun"},{"key":"2341_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120580","volume":"578","author":"NK Fuloria","year":"2026","unstructured":"Fuloria NK, Sekar M, Porwal O, Ansari MT, Biswas A, Narain K et al (2026) Neurofilament light chain in Alzheimer\u2019s disease. Clin Chim Acta 578:120580","journal-title":"Clin Chim Acta"},{"key":"2341_CR57","doi-asserted-by":"publisher","first-page":"937133","DOI":"10.3389\/fnmol.2022.937133\/full","volume":"15","author":"P Goel","year":"2022","unstructured":"Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S (2022) Neuronal cell death mechanisms in Alzheimer\u2019s disease: an insight. Front Mol Neurosci 15:937133. https:\/\/doi.org\/10.3389\/fnmol.2022.937133\/full","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"2341_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00909-x","volume":"20","author":"K Gong","year":"2025","unstructured":"Gong K, Timsina J, Ali M, Chen Y, Liu M, Wang C et al (2025) High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer\u2019s disease phenotypes in a large mixed-dementia cohort. Mol Neurodegener 20(1):120. https:\/\/doi.org\/10.1186\/s13024-025-00909-x","journal-title":"Mol Neurodegener"},{"key":"2341_CR59","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2019.12.034","volume":"319","author":"D Gopalan","year":"2020","unstructured":"Gopalan D, Pandey A, Udupa N, Mutalik S (2020) Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: role of surface engineered nanocarriers. J Control Release 319:183\u2013200","journal-title":"J Control Release"},{"issue":"3","key":"2341_CR60","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/alz.12205","volume":"17","author":"E Granot\u2010Hershkovitz","year":"2021","unstructured":"Granot\u2010Hershkovitz E, Tarraf W, Kurniansyah N, Daviglus M, Isasi CR, Kaplan R et al (2021) APOE alleles\u2019 association with cognitive function differs across Hispanic\/Latino groups and genetic ancestry in the study of Latinos\u2010investigation of neurocognitive aging (HCHS\/SOL). Alzheimers Dement 17(3):466\u2013474. https:\/\/doi.org\/10.1002\/alz.12205","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2341_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","volume":"21","author":"SM Greenberg","year":"2025","unstructured":"Greenberg SM, Bax F, van Veluw SJ (2025) Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms. Nat Rev Neurol 21(4):193\u2013203","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"2341_CR62","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/pharmaceutics17020226","volume":"17","author":"Y Gvozdeva","year":"2025","unstructured":"Gvozdeva Y, Staynova R (2025) pH-dependent drug delivery systems for ulcerative colitis treatment. Pharmaceutics 17(2):226","journal-title":"Pharmaceutics"},{"issue":"2","key":"2341_CR63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2967\/jnumed.120.244061","volume":"62","author":"J Hammes","year":"2021","unstructured":"Hammes J, Bischof GN, Bohn KP, Onur \u00d6, Schneider A, Fliessbach K et al (2021) One-stop shop: 18 F-Flortaucipir PET differentiates amyloid-positive and -negative forms of neurodegenerative diseases. J Nucl Med 62(2):240\u2013246. https:\/\/doi.org\/10.2967\/jnumed.120.244061","journal-title":"J Nucl Med"},{"issue":"1","key":"2341_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P (2019) Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther 11(1):34. https:\/\/doi.org\/10.1186\/s13195-019-0485-0","journal-title":"Alzheimers Res Ther"},{"key":"2341_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70176","author":"J Hardy","year":"2025","unstructured":"Hardy J (2025) Alzheimer\u2019s disease: treatment challenges for the future. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.70176","journal-title":"J Neurochem"},{"key":"2341_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.878942\/full","volume":"9","author":"NM Hendrikse","year":"2022","unstructured":"Hendrikse NM, Llinares Garcia J, Vetter T, Humphreys AJ, Ehmann F (2022) Biomarkers in medicines development\u2014from discovery to regulatory qualification and beyond. Front Med 9:878942. https:\/\/doi.org\/10.3389\/fmed.2022.878942\/full","journal-title":"Front Med"},{"issue":"2","key":"2341_CR67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/brainsci12020146","volume":"12","author":"K Herholz","year":"2022","unstructured":"Herholz K (2022) Imaging clinical subtypes and associated brain networks in Alzheimer\u2019s disease. Brain Sci 12(2):146","journal-title":"Brain Sci"},{"issue":"8","key":"2341_CR68","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/ijms23084153","volume":"23","author":"AM Hersh","year":"2022","unstructured":"Hersh AM, Alomari S, Tyler BM (2022) Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci 23(8):4153","journal-title":"Int J Mol Sci"},{"key":"2341_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110036","volume":"257","author":"GSV Higa","year":"2024","unstructured":"Higa GSV, Viana FJC, Francis-Oliveira J, Cruvinel E, Franchin TS, Marcourakis T et al (2024) Serotonergic neuromodulation of synaptic plasticity. Neuropharmacology 257:110036","journal-title":"Neuropharmacology"},{"issue":"6","key":"2341_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060824","volume":"15","author":"X Hong","year":"2025","unstructured":"Hong X, Huang L, Lei F, Li T, Luo Y, Zeng M et al (2025) The role and pathogenesis of tau protein in Alzheimer\u2019s disease. Biomolecules 15(6):824","journal-title":"Biomolecules"},{"issue":"4","key":"2341_CR71","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1002\/prp2.70131","volume":"13","author":"MS Hossain","year":"2025","unstructured":"Hossain MS, Hussain MH (2025) Multi\u2010target drug design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations. Pharmacol Res Perspect 13(4):e70131. https:\/\/doi.org\/10.1002\/prp2.70131","journal-title":"Pharmacol Res Perspect"},{"key":"2341_CR72","doi-asserted-by":"publisher","unstructured":"Hu L, Tao Y, Jiang Y, Qin F (2023) Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2023.1228679\/full","DOI":"10.3389\/fcell.2023.1228679\/full"},{"issue":"1","key":"2341_CR73","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1038\/s41467-023-41241-6","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Wen J, Ramirez LM, G\u00fcm\u00fc\u015fdil E, Pokhrel P, Man VH et al (2023) Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology. Nat Commun 14(1):5444","journal-title":"Nat Commun"},{"key":"2341_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.899251\/full","volume":"16","author":"LA Hulshof","year":"2022","unstructured":"Hulshof LA, van Nuijs D, Hol EM, Middeldorp J (2022) The role of astrocytes in synapse loss in alzheimer\u2019s disease: a systematic review. Front Cell Neurosci 16:899251. https:\/\/doi.org\/10.3389\/fncel.2022.899251\/full","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"2341_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/jamia\/ocae274","volume":"32","author":"B Idnay","year":"2025","unstructured":"Idnay B, Zhang G, Chen F, Ta CN, Schelke MW, Marder K et al (2025) Mini-mental status examination phenotyping for Alzheimer\u2019s disease patients using both structured and narrative electronic health record features. J Am Med Inform Assoc 32(1):119\u2013128","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"2341_CR76","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-020-02175-1","volume":"140","author":"MD Ikonomovic","year":"2020","unstructured":"Ikonomovic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE et al (2020) Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-\u03b2 plaques in Alzheimer\u2019s disease. Acta Neuropathol 140(4):463\u2013476. https:\/\/doi.org\/10.1007\/s00401-020-02175-1","journal-title":"Acta Neuropathol"},{"key":"2341_CR77","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jconrel.2023.08.001","volume":"361","author":"LL Israel","year":"2023","unstructured":"Israel LL, Sun T, Braubach O, Cox A, Shatalova ES, Rashid HM et al (2023) \u03b2-Amyloid targeting nanodrug for neuron-specific delivery of nucleic acids in Alzheimer\u2019s disease mouse models. J Control Release 361:636\u2013658","journal-title":"J Control Release"},{"issue":"2","key":"2341_CR78","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H et al (2022) Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p\u2010tau. Alzheimers Dement 18(2):283\u2013293. https:\/\/doi.org\/10.1002\/alz.12395","journal-title":"Alzheimers Dement"},{"key":"2341_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101496","volume":"72","author":"D Jeremic","year":"2021","unstructured":"Jeremic D, Jim\u00e9nez-D\u00edaz L, Navarro-L\u00f3pez JD (2021) Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: a systematic review. Ageing Res Rev 72:101496","journal-title":"Ageing Res Rev"},{"key":"2341_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbrc.2023.02.076","volume":"658","author":"YL Jia","year":"2023","unstructured":"Jia YL, Wang W, Han N, Sun HL, Dong FM, Song YX et al (2023) The mitochondria-targeted small molecule SS31 delays progression of behavioral deficits by attenuating \u03b2-amyloid plaque formation and mitochondrial\/synaptic deterioration in APP\/PS1 mice. Biochem Biophys Res Commun 658:36\u201343","journal-title":"Biochem Biophys Res Commun"},{"key":"2341_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-025-01877-1","author":"H Jiang","year":"2025","unstructured":"Jiang H, Escamilla S, Beestrum M, Salas-Lucia F (2025) Cost-effectiveness of testing biofluid biomarkers to diagnose Alzheimer\u2019s disease: a systematic review. Eur J Heal Econ. https:\/\/doi.org\/10.1007\/s10198-025-01877-1","journal-title":"Eur J Heal Econ"},{"issue":"1","key":"2341_CR82","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/0115672050301407240408033046","volume":"21","author":"S Kalyaanamoorthy","year":"2024","unstructured":"Kalyaanamoorthy S, Opare SK, Xu X, Ganesan A, Rao PPN (2024) Post-Translational Modifications in Tau and Their Roles in Alzheimer\u2019s Pathology. Curr Alzheimer Res 21(1):24\u201349","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"2341_CR83","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/03639045.2021.1934861","volume":"47","author":"LS Kandil","year":"2021","unstructured":"Kandil LS, Farid RM, ElGamal SS, Hanafy AS (2021) Intranasal galantamine\/chitosan complex nanoparticles elicit neuroprotection potentials in rat brains via antioxidant effect. Drug Dev Ind Pharm 47(5):735\u2013740. https:\/\/doi.org\/10.1080\/03639045.2021.1934861","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"2341_CR84","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1161\/STROKEAHA.122.041444","volume":"54","author":"ZS Katusic","year":"2023","unstructured":"Katusic ZS, D\u2019Uscio LV, He T (2023) Emerging roles of endothelial nitric oxide in preservation of cognitive health. Stroke 54(3):686\u2013696. https:\/\/doi.org\/10.1161\/STROKEAHA.122.041444","journal-title":"Stroke"},{"issue":"5","key":"2341_CR85","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/02652048.2020.1756971","volume":"37","author":"A Kaur","year":"2020","unstructured":"Kaur A, Nigam K, Srivastava S, Tyagi A, Dang S (2020) Memantine nanoemulsion: a new approach to treat Alzheimer\u2019s disease. J Microencapsul 37(5):355\u2013365. https:\/\/doi.org\/10.1080\/02652048.2020.1756971","journal-title":"J Microencapsul"},{"issue":"1","key":"2341_CR86","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2020.1840913","volume":"9","author":"M Kaya","year":"2021","unstructured":"Kaya M, Ahishali B (2021) Basic physiology of the blood-brain barrier in health and disease: a brief overview. Tissue Barriers 9(1):1840913. https:\/\/doi.org\/10.1080\/21688370.2020.1840913","journal-title":"Tissue Barriers"},{"issue":"4","key":"2341_CR87","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/1567201818666211021160441","volume":"19","author":"R Kharwade","year":"2022","unstructured":"Kharwade R, Badole P, Mahajan N, More S (2022) Toxicity and surface modification of dendrimers: a critical review. Curr Drug Deliv 19(4):451\u2013465","journal-title":"Curr Drug Deliv"},{"issue":"9","key":"2341_CR88","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang KA (2023) GFAP as a potential biomarker for Alzheimer\u2019s disease: a systematic review and meta-analysis. Cells 12(9):1309","journal-title":"Cells"},{"issue":"4","key":"2341_CR89","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3390\/ijms27042030","volume":"27","author":"KH Kim","year":"2026","unstructured":"Kim KH, Yoo M, Choi MY, Yoo BC (2026) A practical roadmap for clinical translation of metabolic biomarkers: a review. Int J Mol Sci 27(4):2030","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2341_CR90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT et al (2021) Alzheimer disease. Nat Rev Dis Prim 7(1):33","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"2341_CR91","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05417-z","volume":"63","author":"U Kochman","year":"2026","unstructured":"Kochman U, Sitka H, Ku\u017aniar J, Czaja M, Kozubek P, Besz\u0142ej JA et al (2026) Targeted nanoparticles for drug delivery across the blood\u2013brain barrier in early and late stages of Alzheimer\u2019s disease: a review. Mol Neurobiol 63(1):75. https:\/\/doi.org\/10.1007\/s12035-025-05417-z","journal-title":"Mol Neurobiol"},{"issue":"3","key":"2341_CR92","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1021\/acs.orglett.0c03597","volume":"23","author":"I Kocsis","year":"2021","unstructured":"Kocsis I, Sanna E, Hunter CA (2021) Liposome enhanced detection of amyloid protein aggregates. Org Lett 23(3):647\u2013650. https:\/\/doi.org\/10.1021\/acs.orglett.0c03597","journal-title":"Org Lett"},{"key":"2341_CR93","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/IJN.S439181","volume":"19","author":"J Koo","year":"2024","unstructured":"Koo J, Lim C, Oh KT (2024) Recent advances in intranasal administration for brain-targeting delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations. Int J Nanomedicine 19:1767\u20131807","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"2341_CR94","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1021\/acs.nanolett.2c05056","volume":"23","author":"D Kou","year":"2023","unstructured":"Kou D, Gao Y, Li C, Zhou D, Lu K, Wang N et al (2023) Intranasal pathway for nanoparticles to enter the central nervous system. Nano Lett 23(11):5381\u20135390. https:\/\/doi.org\/10.1021\/acs.nanolett.2c05056","journal-title":"Nano Lett"},{"issue":"4","key":"2341_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109042","volume":"35","author":"JN Kuehner","year":"2021","unstructured":"Kuehner JN, Chen J, Bruggeman EC, Wang F, Li Y, Xu C et al (2021) 5-hydroxymethylcytosine is dynamically regulated during forebrain organoid development and aberrantly altered in Alzheimer\u2019s disease. Cell Rep 35(4):109042","journal-title":"Cell Rep"},{"issue":"10","key":"2341_CR96","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/biom15101365","volume":"15","author":"S Kumari","year":"2025","unstructured":"Kumari S, Singh AK, Kumar M, Pradhan R, Rao AR, Yadav Y et al (2025) Targeting a Tau kinase Cdk5, cyclin-dependent kinase: a blood-based diagnostic marker and therapeutic earmark for alzheimer\u2019s disease. Biomolecules 15(10):1365","journal-title":"Biomolecules"},{"issue":"4","key":"2341_CR97","doi-asserted-by":"publisher","first-page":"764","DOI":"10.2174\/1570159X21666230216094353","volume":"21","author":"S Kushwah","year":"2023","unstructured":"Kushwah S, Maurya NS, Kushwaha S, Scotti L, Chawade A, Mani A (2023) Herbal therapeutics for Alzheimer\u2019s disease: ancient indian medicine system from the modern viewpoint. Curr Neuropharmacol 21(4):764\u2013776","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"2341_CR98","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3233\/JAD-215244","volume":"85","author":"S Kwak","year":"2022","unstructured":"Kwak S, Oh DJ, Jeon YJ, Oh DY, Park SM, Kim H et al (2022) Utility of machine learning approach with neuropsychological tests in predicting functional impairment of Alzheimer\u2019s disease. J Alzheimers Dis 85(3):1357\u20131372. https:\/\/doi.org\/10.3233\/JAD-215244","journal-title":"J Alzheimers Dis"},{"key":"2341_CR99","doi-asserted-by":"publisher","first-page":"1607669","DOI":"10.3389\/fnagi.2025.1607669\/full","volume":"17","author":"L Lado","year":"2026","unstructured":"Lado L, Misir A (2026) The interplay of homeostasis, inflammation, and oxidative stress in neurodegenerative disorders: the role of biological markers, antioxidants, lithium, and TMS\u2014a proposed framework for preventing neurodegenerative disorders through biomarkers and multim. Front Aging Neurosci 17:1607669. https:\/\/doi.org\/10.3389\/fnagi.2025.1607669\/full","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"2341_CR100","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1212\/CPJ.0000000000001049","volume":"11","author":"T Langheinrich","year":"2021","unstructured":"Langheinrich T, Kobylecki C, Jones M, Thompson JC, Snowden JS, Hinz R et al (2021) Amyloid-PET\u2013positive patient with bvFTD. Neurol Clin Pract 11(6):e952\u2013e955. https:\/\/doi.org\/10.1212\/CPJ.0000000000001049","journal-title":"Neurol Clin Pract"},{"key":"2341_CR101","doi-asserted-by":"crossref","unstructured":"Lara MM, Cameron HS, Daniel Y, Angus PRJ (2022) WIREs nanomedicine and nanobiotechnology. Issue Information 14(6)","DOI":"10.1002\/wnan.1728"},{"key":"2341_CR102","doi-asserted-by":"publisher","unstructured":"Le HT, Lau ECY, Lu CY, Hilmer SN, Jeon Y, Low L et al 2025 Treatment modifiers and predictors of risperidone response in dementia: An individual participant data meta\u2010analysis of six randomized controlled trials. Alzheimer\u2019s Dement https:\/\/doi.org\/10.1002\/alz.70665","DOI":"10.1002\/alz.70665"},{"key":"2341_CR103","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jconrel.2021.02.010","volume":"332","author":"H Lea-Banks","year":"2021","unstructured":"Lea-Banks H, Meng Y, Wu SK, Belhadjhamida R, Hamani C, Hynynen K (2021) Ultrasound-sensitive nanodroplets achieve targeted neuromodulation. J Control Release 332:30\u201339","journal-title":"J Control Release"},{"issue":"12","key":"2341_CR104","doi-asserted-by":"publisher","first-page":"9146","DOI":"10.21037\/qims-24-1100","volume":"14","author":"TH Lee","year":"2024","unstructured":"Lee TH, Wang YF, Peng NJ, Peng SJ (2024) Voxel-based evaluation for [18F] florbetaben brain \u03b2-amyloid positron emission tomography of healthy control, mild cognitive impairment, and Alzheimer\u2019s disease. Quant Imaging Med Surg 14(12):9146\u20139156","journal-title":"Quant Imaging Med Surg"},{"issue":"11","key":"2341_CR105","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/brainsci11111491","volume":"11","author":"L Lenhart","year":"2021","unstructured":"Lenhart L, Seiler S, Pirpamer L, Goebel G, Potrusil T, Wagner M et al (2021) Anatomically standardized detection of MRI atrophy patterns in early-stage Alzheimer\u2019s disease. Brain Sci 11(11):1491","journal-title":"Brain Sci"},{"issue":"7","key":"2341_CR106","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00259-021-05401-4","volume":"48","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N et al (2021) A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging 48(7):2295\u20132305. https:\/\/doi.org\/10.1007\/s00259-021-05401-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"45","key":"2341_CR107","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023076","volume":"99","author":"W Li","year":"2020","unstructured":"Li W, Wei Z, Liu X (2020) Clinical efficacy of sertraline in the treatment of depression caused by Alzheimer disease. Medicine (Baltimore) 99(45):e23076. https:\/\/doi.org\/10.1097\/MD.0000000000023076","journal-title":"Medicine (Baltimore)"},{"key":"2341_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101090","author":"J Li","year":"2021","unstructured":"Li J, Zheng M, Shimoni O, Banks WA, Bush AI, Gamble JR et al (2021a) Development of novel therapeutics targeting the blood\u2013brain barrier: from barrier to carrier. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202101090","journal-title":"Adv Sci"},{"issue":"17","key":"2341_CR109","doi-asserted-by":"publisher","first-page":"21791","DOI":"10.18632\/aging.203482","volume":"13","author":"S Li","year":"2021","unstructured":"Li S, Wang C, Wang Z, Tan J (2021b) Involvement of cerebrovascular abnormalities in the pathogenesis and progression of Alzheimer\u2019s disease: an adrenergic approach. Aging (Albany NY) 13(17):21791\u201321806. https:\/\/doi.org\/10.18632\/aging.203482","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"2341_CR110","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1039\/D5PM00148J","volume":"2","author":"H Li","year":"2025","unstructured":"Li H, Shen X, Zhang B, Li Y, Alexander C, Harvey P et al (2025) Brain-targeted intranasal delivery of biologics: a perspective for Alzheimer\u2019s disease treatment. RSC Pharm 2(6):1323\u20131348","journal-title":"RSC Pharm"},{"issue":"1","key":"2341_CR111","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/s41467-023-37240-2","volume":"14","author":"A Lia","year":"2023","unstructured":"Lia A, Sansevero G, Chiavegato A, Sbrissa M, Pendin D, Mariotti L et al (2023) Rescue of astrocyte activity by the calcium sensor STIM1 restores long-term synaptic plasticity in female mice modelling Alzheimer\u2019s disease. Nat Commun 14(1):1590","journal-title":"Nat Commun"},{"key":"2341_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747.pub4","volume":"11","author":"AWY Lim","year":"2024","unstructured":"Lim AWY, Schneider L, Loy C (2024) Galantamine for dementia due to Alzheimer\u2019s disease and mild cognitive impairment. Cochrane Database Syst Rev 11:CD001747. https:\/\/doi.org\/10.1002\/14651858.CD001747.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2341_CR113","doi-asserted-by":"publisher","first-page":"1420731","DOI":"10.3389\/fnagi.2024.1420731\/full","volume":"16","author":"C Lin","year":"2024","unstructured":"Lin C, Kong Y, Chen Q, Zeng J, Pan X, Miao J (2024) Decoding sTREM2: its impact on Alzheimer\u2019s disease\u2014a comprehensive review of mechanisms and implications. Front Aging Neurosci 16:1420731. https:\/\/doi.org\/10.3389\/fnagi.2024.1420731\/full","journal-title":"Front Aging Neurosci"},{"key":"2341_CR114","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jconrel.2022.05.038","volume":"348","author":"S Linciano","year":"2022","unstructured":"Linciano S, Moro G, Zorzi A, Angelini A (2022) Molecular analysis and therapeutic applications of human serum albumin-fatty acid interactions. J Control Release 348:115\u2013126","journal-title":"J Control Release"},{"key":"2341_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102697","volume":"62","author":"Q Liu","year":"2023","unstructured":"Liu Q, Wang X, Hu Y, Zhao JN, Huang CH, Li T et al (2023) Acetylated tau exacerbates learning and memory impairment by disturbing with mitochondrial homeostasis. Redox Biol 62:102697","journal-title":"Redox Biol"},{"key":"2341_CR116","doi-asserted-by":"publisher","unstructured":"Lukacsovich D, O\u2019Shea D, Huang H, Zhang W, Young JI, Chen XS, et al (2023) MIAMI-AD (Methylation in Aging and Methylation in AD): an integrative knowledgebase that facilitates explorations of DNA methylation across sex, aging, and Alzheimer\u2019s disease https:\/\/doi.org\/10.1101\/2023.12.04.23299412","DOI":"10.1101\/2023.12.04.23299412"},{"issue":"6","key":"2341_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9060472","volume":"9","author":"RJ Mailloux","year":"2020","unstructured":"Mailloux RJ (2020) An update on mitochondrial reactive oxygen species production. Antioxidants (Basel) 9(6):472","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"2341_CR118","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/ijms19061637","volume":"19","author":"P Maiti","year":"2018","unstructured":"Maiti P, Dunbar G (2018) Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci 19(6):1637","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2341_CR119","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/acs.jcim.2c01597","volume":"63","author":"VH Man","year":"2023","unstructured":"Man VH, He X, Han F, Cai L, Wang L, Niu T et al (2023) Phosphorylation at Ser289 enhances the oligomerization of tau repeat R2. J Chem Inf Model 63(4):1351\u20131361. https:\/\/doi.org\/10.1021\/acs.jcim.2c01597","journal-title":"J Chem Inf Model"},{"issue":"8","key":"2341_CR120","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jcmg.2024.06.002","volume":"17","author":"A Masri","year":"2024","unstructured":"Masri A (2024) Linking amyloid burden to prognosis. JACC Cardiovasc Imaging 17(8):923\u2013925","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"2341_CR121","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41580-022-00566-8","volume":"24","author":"JS Mattick","year":"2023","unstructured":"Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL et al (2023) Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol 24(6):430\u2013447","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2341_CR122","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, Ossenkoppele R, Jonsson M, Seeley W et al (2022) Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98(11):e1137\u2013e1150. https:\/\/doi.org\/10.1212\/WNL.0000000000200040","journal-title":"Neurology"},{"key":"2341_CR123","doi-asserted-by":"publisher","first-page":"1360195","DOI":"10.3389\/fncel.2024.1360195\/full","volume":"18","author":"MG Mayer","year":"2024","unstructured":"Mayer MG, Fischer T (2024) Microglia at the blood brain barrier in health and disease. Front Cell Neurosci 18:1360195. https:\/\/doi.org\/10.3389\/fncel.2024.1360195\/full","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"2341_CR124","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JAD-200228","volume":"78","author":"AM Mezlini","year":"2020","unstructured":"Mezlini AM, Magdamo C, Merrill E, Chibnik LB, Blacker DL, Hyman BT et al (2020) Characterizing clinical and neuropathological traits of APOE haplotypes in African Americans and Europeans. J Alzheimers Dis 78(1):467\u2013477","journal-title":"J Alzheimers Dis"},{"key":"2341_CR125","doi-asserted-by":"publisher","unstructured":"Misrani A, Tabassum S, Yang L 2021 Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease. Front Aging Neurosci https:\/\/doi.org\/10.3389\/fnagi.2021.617588\/full","DOI":"10.3389\/fnagi.2021.617588\/full"},{"issue":"11","key":"2341_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000946","volume":"18","author":"P Mora","year":"2020","unstructured":"Mora P, Hollier PL, Guimbal S, Abelanet A, Diop A, Cornuault L et al (2020) Blood\u2013brain barrier genetic disruption leads to protective barrier formation at the glia limitans. PLoS Biol 18(11):e3000946. https:\/\/doi.org\/10.1371\/journal.pbio.3000946","journal-title":"PLoS Biol"},{"issue":"4","key":"2341_CR127","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/pharmaceutics15041054","volume":"15","author":"DA Moreira","year":"2023","unstructured":"Moreira DA, Santos SD, Leiro V, P\u00eago AP (2023) Dendrimers and derivatives as multifunctional nanotherapeutics for Alzheimer\u2019s disease. Pharmaceutics 15(4):1054","journal-title":"Pharmaceutics"},{"issue":"16","key":"2341_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169328","volume":"23","author":"C Mor\u00e9n","year":"2022","unstructured":"Mor\u00e9n C, DeSouza RM, Giraldo DM, Uff C (2022) Antioxidant therapeutic strategies in neurodegenerative diseases. Int J Mol Sci 23(16):9328","journal-title":"Int J Mol Sci"},{"key":"2341_CR129","doi-asserted-by":"publisher","unstructured":"Mottaqi M, Zhang P, Xie L (2025) Integrating explainable artificial intelligence with multiomics systems biology and electronic health record data mining for personalized drug repurposing in Alzheimer\u2019s disease. Brief Bioinform https:\/\/doi.org\/10.1093\/bib\/bbaf623\/8351048","DOI":"10.1093\/bib\/bbaf623\/8351048"},{"issue":"5","key":"2341_CR130","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/cancers16050995","volume":"16","author":"S Mucherino","year":"2024","unstructured":"Mucherino S, Lorenzoni V, Triulzi I, Del Re M, Orlando V, Capuano A et al (2024) Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review. Cancers (Basel) 16(5):995","journal-title":"Cancers (Basel)"},{"key":"2341_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105047","volume":"89","author":"DS Nady","year":"2023","unstructured":"Nady DS, Bakowsky U, Fahmy SA (2023) Recent advances in brain delivery of synthetic and natural nano therapeutics: reviving hope for Alzheimer\u2019s disease patients. J Drug Deliv Sci Technol 89:105047","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"2341_CR132","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s12031-021-01829-3","volume":"71","author":"P Nagu","year":"2021","unstructured":"Nagu P, Parashar A, Behl T, Mehta V (2021) Gut microbiota composition and epigenetic molecular changes connected to the pathogenesis of Alzheimer\u2019s disease. J Mol Neurosci 71(7):1436\u20131455. https:\/\/doi.org\/10.1007\/s12031-021-01829-3","journal-title":"J Mol Neurosci"},{"issue":"5","key":"2341_CR133","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1017\/S135561772200042X","volume":"29","author":"J Nicosia","year":"2023","unstructured":"Nicosia J, Aschenbrenner AJ, Balota DA, Sliwinski MJ, Tahan M, Adams S et al (2023) Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer\u2019s disease. J Int Neuropsychol Soc 29(5):459\u2013471","journal-title":"J Int Neuropsychol Soc"},{"issue":"2","key":"2341_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021168","volume":"25","author":"K Nijakowski","year":"2024","unstructured":"Nijakowski K, Owecki W, Jankowski J, Surdacka A (2024) Salivary biomarkers for Alzheimer\u2019s disease: a systematic review with meta-analysis. Int J Mol Sci 25(2):1168","journal-title":"Int J Mol Sci"},{"key":"2341_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117394","volume":"245","author":"P Nirale","year":"2020","unstructured":"Nirale P, Paul A, Yadav KS (2020) Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer\u2019s. Parkinson\u2019s and Prion\u2019s Life Sci 245:117394","journal-title":"Parkinson\u2019s and Prion\u2019s Life Sci"},{"key":"2341_CR136","unstructured":"ClinicalTrials.gov. Comparative assessment of clinical efficacy of donepezil between the patients with Alzheimer's disease and mixed dementia [Internet]. Bethesda (MD): National Library of Medicine (US); 2007 [cited 2026 Aug 13]. Identifier: NCT01023867. https:\/\/clinicaltrials.gov\/study\/NCT01023867"},{"key":"2341_CR137","unstructured":"ClinicalTrials.gov. Changes of cognitive function in patients with mild to moderate Alzheimer's disease associated with or without white matter changes after rivastigmine patch therapy [Internet]. Bethesda (MD): National Library of Medicine (US); 2011 [cited 2026 Aug 13]. Identifier: NCT01380288. https:\/\/clinicaltrials.gov\/study\/NCT01380288"},{"key":"2341_CR138","unstructured":"ClinicalTrials.gov. A randomized, double-blind, placebo-controlled trial of long-term (2-year) treatment of galantamine in mild to moderately-severe Alzheimer's disease [Internet]. Bethesda (MD): National Library of Medicine (US); 2008 [cited 2026 Aug 13]. Identifier: NCT00679627. https:\/\/clinicaltrials.gov\/study\/NCT00679627"},{"key":"2341_CR139","unstructured":"ClinicalTrials.gov. The use of memantine for prevention of Alzheimer's disease [Internet]. Bethesda (MD): National Library of Medicine (US); 2021 [cited 2026 Aug 13]. Identifier: NCT05063851. https:\/\/clinicaltrials.gov\/study\/NCT05063851"},{"key":"2341_CR145","unstructured":"ClinicalTrials.gov. A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer's disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205 [Internet]. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2026 Aug 13]. identifier: NCT04241068. https:\/\/clinicaltrials.gov\/study\/NCT04241068"},{"key":"2341_CR140","unstructured":"ClinicalTrials.gov. A placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer's disease [Internet]. Bethesda (MD): National Library of Medicine (US); 2019 [cited 2026 Aug 13]. Identifier: NCT03887455. https:\/\/clinicaltrials.gov\/study\/NCT03887455"},{"key":"2341_CR141","unstructured":"ClinicalTrials.gov. Assessment of safety, tolerability, and efficacy of donanemab in early symptomatic Alzheimer's disease [Internet]. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2026 Aug 13]. Identifier: NCT04437511. https:\/\/clinicaltrials.gov\/study\/NCT04437511"},{"key":"2341_CR142","unstructured":"ClinicalTrials.gov. Depression in Alzheimer's disease (DIADS-2) [Internet]. Bethesda (MD): National Library of Medicine (US); 2004 [cited 2026 Aug 13]. Identifier: NCT00086138. https:\/\/clinicaltrials.gov\/study\/NCT00086138"},{"key":"2341_CR143","unstructured":"ClinicalTrials.gov. A randomized, double-blind, placebo-controlled study of risperidone for treatment of behavioral disturbances in subjects with dementia [Internet]. Bethesda (MD): National Library of Medicine (US); 2004 [cited 2026 Aug 13]. Identifier: NCT00253123. https:\/\/clinicaltrials.gov\/study\/NCT00253123"},{"key":"2341_CR144","unstructured":"ClinicalTrials.gov. 18-month double-blind, placebo-controlled study of curcumin [Internet]. Bethesda (MD): National Library of Medicine (US); 2011 [cited 2026 Aug 13]. Identifier: NCT01383161. https:\/\/clinicaltrials.gov\/study\/NCT01383161"},{"key":"2341_CR146","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fnagi.2020.00185\/full","volume":"12","author":"CR Noe","year":"2020","unstructured":"Noe CR, Noe-Letschnig M, Handschuh P, Noe CA, Lanzenberger R (2020) Dysfunction of the blood-brain barrier\u2014a key step in neurodegeneration and dementia. Front Aging Neurosci 12:185. https:\/\/doi.org\/10.3389\/fnagi.2020.00185\/full","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2341_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30040848","volume":"30","author":"T Numakawa","year":"2025","unstructured":"Numakawa T, Kajihara R (2025) The role of brain-derived neurotrophic factor as an essential mediator in neuronal functions and the therapeutic potential of its mimetics for neuroprotection in neurologic and psychiatric disorders. Molecules 30(4):848","journal-title":"Molecules"},{"issue":"1","key":"2341_CR148","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1874609814666210302085232","volume":"15","author":"JO Ogbodo","year":"2022","unstructured":"Ogbodo JO, Agbo CP, Njoku UO, Ogugofor MO, Egba SI, Ihim SA et al (2022) Alzheimer\u2019s disease: pathogenesis and therapeutic interventions. Curr Aging Sci 15(1):2\u201325","journal-title":"Curr Aging Sci"},{"issue":"18","key":"2341_CR149","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.neuron.2022.06.021","volume":"110","author":"M Otero-Garcia","year":"2022","unstructured":"Otero-Garcia M, Mahajani SU, Wakhloo D, Tang W, Xue YQ, Morabito S et al (2022) Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer\u2019s disease. Neuron 110(18):2929-2948.e8","journal-title":"Neuron"},{"issue":"10","key":"2341_CR150","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1089\/ars.2019.7962","volume":"32","author":"FR Palma","year":"2020","unstructured":"Palma FR, He C, Danes JM, Paviani V, Coelho DR, Gantner BN et al (2020) Mitochondrial superoxide dismutase: what the established, the intriguing, and the novel reveal about a key cellular redox switch. Antioxid Redox Signal 32(10):701\u2013714. https:\/\/doi.org\/10.1089\/ars.2019.7962","journal-title":"Antioxid Redox Signal"},{"issue":"9","key":"2341_CR151","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tins.2023.06.003","volume":"46","author":"JM Palmer","year":"2023","unstructured":"Palmer JM, Huentelman M, Ryan L (2023) More than just risk for Alzheimer\u2019s disease: APOE \u03b54\u2019s impact on the aging brain. Trends Neurosci 46(9):750\u2013763","journal-title":"Trends Neurosci"},{"issue":"8","key":"2341_CR152","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772","journal-title":"JAMA"},{"issue":"7","key":"2341_CR153","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/13543784.2023.2233892","volume":"32","author":"F Panza","year":"2023","unstructured":"Panza F, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L et al (2023) Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin Investig Drugs 32(7):625\u2013634. https:\/\/doi.org\/10.1080\/13543784.2023.2233892","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"2341_CR154","doi-asserted-by":"publisher","first-page":"8976","DOI":"10.3390\/ijms24108976","volume":"24","author":"V Papaliagkas","year":"2023","unstructured":"Papaliagkas V, Kalinderi K, Vareltzis P, Moraitou D, Papamitsou T, Chatzidimitriou M (2023) CSF biomarkers in the early diagnosis of mild cognitive impairment and alzheimer\u2019s disease. Int J Mol Sci 24(10):8976","journal-title":"Int J Mol Sci"},{"key":"2341_CR155","doi-asserted-by":"publisher","unstructured":"Park JH 2020 Machine-learning algorithms based on screening tests for mild cognitive impairment. Am J Alzheimer\u2019s Dis Other Dementias\u00ae https:\/\/doi.org\/10.1177\/1533317520927163","DOI":"10.1177\/1533317520927163"},{"issue":"1","key":"2341_CR156","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-022-01078-9","volume":"7","author":"J Park","year":"2022","unstructured":"Park J, Lee K, Kim K, Yi SJ (2022) The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther 7(1):217","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"2341_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213954","volume":"23","author":"E Passeri","year":"2022","unstructured":"Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A et al (2022) Alzheimer\u2019s disease: treatment strategies and their limitations. Int J Mol Sci 23(22):13954","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2341_CR158","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4155\/tde-2022-0018","volume":"13","author":"D Patel","year":"2022","unstructured":"Patel D, Thakkar H (2022) Formulation considerations for improving intranasal delivery of CNS acting therapeutics. Ther Deliv 13(7):371\u2013381. https:\/\/doi.org\/10.4155\/tde-2022-0018","journal-title":"Ther Deliv"},{"issue":"1","key":"2341_CR159","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/0118715249281331240325042642","volume":"25","author":"K Pathak","year":"2025","unstructured":"Pathak K, Ahmad MZ, Saikia R, Pathak MP, Sahariah JJ, Kalita P et al (2025) Nanomedicine: a new frontier in Alzheimer\u2019s disease drug targeting. Cent Nerv Syst Agents Med Chem 25(1):3\u201319","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"19","key":"2341_CR160","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2174\/0115680266295495240415114919","volume":"24","author":"M Patwekar","year":"2024","unstructured":"Patwekar M, Patwekar F, Khan S, Sharma R, Kumar D (2024) Navigating the Alzheimer\u2019s treatment landscape: unraveling amyloid-beta complexities and pioneering precision medicine approaches. Curr Top Med Chem 24(19):1665\u20131682","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"2341_CR161","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13577-026-01368-2","volume":"39","author":"F Patwekar","year":"2026","unstructured":"Patwekar F, Patwekar M, Sharma R, Varghese R, Mohammed A (2026a) Advancing diagnostic biomarkers in Alzheimer\u2019s disease: interdisciplinary innovations and technological frontiers. Hum Cell 39(4):57","journal-title":"Hum Cell"},{"key":"2341_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2026.156421","volume":"281","author":"F Patwekar","year":"2026","unstructured":"Patwekar F, Patwekar M, Sharma R, Varghese R, Mohammed A (2026b) Antibody-based nanoparticles in Alzheimer\u2019s disease: innovations in diagnosis and therapy. Pathol Res Pract 281:156421","journal-title":"Pathol Res Pract"},{"issue":"2","key":"2341_CR163","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pathol.2023.11.002","volume":"56","author":"EC Paver","year":"2024","unstructured":"Paver EC, Morey AL (2024) Biomarkers and biomarker validation: a pathologist\u2019s guide to getting it right. Pathology 56(2):147\u2013157","journal-title":"Pathology"},{"key":"2341_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2024.105790","volume":"178","author":"V Perales-Salinas","year":"2024","unstructured":"Perales-Salinas V, Purushotham SS, Buskila Y (2024) Curcumin as a potential therapeutic agent for treating neurodegenerative diseases. Neurochem Int 178:105790","journal-title":"Neurochem Int"},{"issue":"6","key":"2341_CR165","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/s41380-022-01518-6","volume":"27","author":"D Petit","year":"2022","unstructured":"Petit D, Fern\u00e1ndez SG, Zoltowska KM, Enzlein T, Ryan NS, O\u2019Connor A et al (2022) A\u03b2 profiles generated by Alzheimer\u2019s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry 27(6):2821\u20132832","journal-title":"Mol Psychiatry"},{"key":"2341_CR166","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62929","volume":"10","author":"A Pichet Binette","year":"2021","unstructured":"Pichet Binette A, Theaud G, Rheault F, Roy M, Collins DL, Levin J et al (2021) Bundle-specific associations between white matter microstructure and A\u03b2 and tau pathology in preclinical Alzheimer\u2019s disease. Elife 10:e62929","journal-title":"Elife"},{"issue":"4","key":"2341_CR167","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/10738584211069897","volume":"29","author":"PD Pinky","year":"2023","unstructured":"Pinky PD, Pfitzer JC, Senfeld J, Hong H, Bhattacharya S, Suppiramaniam V et al (2023) Recent insights on glutamatergic dysfunction in Alzheimer\u2019s disease and therapeutic implications. Neuroscientist 29(4):461\u2013471. https:\/\/doi.org\/10.1177\/10738584211069897","journal-title":"Neuroscientist"},{"key":"2341_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105010","volume":"144","author":"SS Plotkin","year":"2020","unstructured":"Plotkin SS, Cashman NR (2020) Passive immunotherapies targeting A\u03b2 and tau in Alzheimer\u2019s disease. Neurobiol Dis 144:105010","journal-title":"Neurobiol Dis"},{"issue":"1","key":"2341_CR169","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41746-025-01583-5","volume":"8","author":"SE Polk","year":"2025","unstructured":"Polk SE, \u00d6hman F, Hassenstab J, K\u00f6nig A, Papp KV, Sch\u00f6ll M et al (2025) A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer\u2019s disease. NPJ Digit Med 8(1):266","journal-title":"NPJ Digit Med"},{"issue":"3","key":"2341_CR170","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s11357-024-01118-y","volume":"46","author":"M Pszczo\u0142owska","year":"2024","unstructured":"Pszczo\u0142owska M, Walczak K, Mi\u015bk\u00f3w W, Mroziak M, Chojdak-\u0141ukasiewicz J, Leszek J (2024) Mitochondrial disorders leading to Alzheimer\u2019s disease\u2014perspectives of diagnosis and treatment. GeroScience 46(3):2977\u20132988. https:\/\/doi.org\/10.1007\/s11357-024-01118-y","journal-title":"GeroScience"},{"issue":"1","key":"2341_CR171","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13148-024-01650-w","volume":"16","author":"Y Qin","year":"2024","unstructured":"Qin Y, Yang P, He W, Li D, Zeng L, Li J et al (2024a) Novel histone post-translational modifications in Alzheimer\u2019s disease: current advances and implications. Clin Epigenetics 16(1):39. https:\/\/doi.org\/10.1186\/s13148-024-01650-w","journal-title":"Clin Epigenetics"},{"issue":"5","key":"2341_CR172","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/ijmm.2024.5371","volume":"53","author":"P Qin","year":"2024","unstructured":"Qin P, Sun Y, Li L (2024b) Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review). Int J Mol Med 53(5):47. https:\/\/doi.org\/10.3892\/ijmm.2024.5371","journal-title":"Int J Mol Med"},{"key":"2341_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202000076","author":"N Rabiee","year":"2021","unstructured":"Rabiee N, Ahmadi S, Afshari R, Khalaji S, Rabiee M, Bagherzadeh M et al (2021) Polymeric nanoparticles for nasal drug delivery to the brain: relevance to Alzheimer\u2019s disease. Adv Ther. https:\/\/doi.org\/10.1002\/adtp.202000076","journal-title":"Adv Ther"},{"key":"2341_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.119857","volume":"562","author":"K Rajendran","year":"2024","unstructured":"Rajendran K, Krishnan UM (2024) Biomarkers in Alzheimer\u2019s disease. Clin Chim Acta 562:119857","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2341_CR175","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC (2022) ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17(1):72. https:\/\/doi.org\/10.1186\/s13024-022-00574-4","journal-title":"Mol Neurodegener"},{"issue":"21","key":"2341_CR176","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH (2022) Phosphorylated Tau in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci 23(21):12841","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2341_CR177","first-page":"1131","volume":"11","author":"VP Reddy","year":"2023","unstructured":"Reddy VP, Aryal P, Soni P (2023) RAGE Inhibitors in Neurodegenerative Diseases Biomedicines 11(4):1131","journal-title":"RAGE Inhibitors in Neurodegenerative Diseases Biomedicines"},{"issue":"1","key":"2341_CR178","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ et al (2020) Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11(1):667","journal-title":"Nat Commun"},{"issue":"1","key":"2341_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynirp.2025.100315","volume":"6","author":"M Rezaei","year":"2026","unstructured":"Rezaei M, Mohammadikhaveh S, Faraji H, Ardalani R, Rezaei M, Shirazinodeh A (2026) Early diagnosis of Alzheimer\u2019s disease based on brain morphological changes: a comprehensive approach combining voxel-based morphometry and deep learning. Neuroimage Rep 6(1):100315","journal-title":"Neuroimage Rep"},{"issue":"4","key":"2341_CR180","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/13872877251324080","volume":"104","author":"N Richter","year":"2025","unstructured":"Richter N, Breidenbach L, Schmieschek MH, Heiss WD, Fink GR, Onur OA (2025) Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes. J Alzheimers Dis 104(4):1290\u20131300. https:\/\/doi.org\/10.1177\/13872877251324080","journal-title":"J Alzheimers Dis"},{"key":"2341_CR181","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neurobiolaging.2019.09.020","volume":"85","author":"JM Riphagen","year":"2020","unstructured":"Riphagen JM, Ramakers IHGM, Freeze WM, Pagen LHG, Hanseeuw BJ, Verbeek MM et al (2020) Linking APOE-\u03b54, blood-brain barrier dysfunction, and inflammation to Alzheimer\u2019s pathology. Neurobiol Aging 85:96\u2013103","journal-title":"Neurobiol Aging"},{"issue":"1","key":"2341_CR182","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010107","volume":"24","author":"AA Rostagno","year":"2022","unstructured":"Rostagno AA (2022) Pathogenesis of Alzheimer\u2019s disease. Int J Mol Sci 24(1):107","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2341_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252211941","volume":"25","author":"F Roveta","year":"2024","unstructured":"Roveta F, Bonino L, Piella EM, Rainero I, Rubino E (2024) Neuroinflammatory biomarkers in Alzheimer\u2019s disease: from pathophysiology to clinical implications. Int J Mol Sci 25(22):11941","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2341_CR184","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/ph17091180","volume":"17","author":"R Safarov","year":"2024","unstructured":"Safarov R, Fedotova O, Uvarova A, Gordienko M, Menshutina N (2024) Review of intranasal active pharmaceutical ingredient delivery systems. Pharmaceuticals (Basel) 17(9):1180","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"2341_CR185","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3390\/ijms25052698","volume":"25","author":"E Scarian","year":"2024","unstructured":"Scarian E, Viola C, Dragoni F, Di Gerlando R, Rizzo B, Diamanti L et al (2024) New insights into oxidative stress and inflammatory response in neurodegenerative diseases. Int J Mol Sci 25(5):2698","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2341_CR186","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ibra.12126","volume":"9","author":"E Scarpa","year":"2023","unstructured":"Scarpa E, Cascione M, Griego A, Pellegrino P, Moschetti G, De Matteis V (2023) Gold and silver nanoparticles in Alzheimer\u2019s and Parkinson\u2019s diagnostics and treatments. Ibrain 9(3):298\u2013315. https:\/\/doi.org\/10.1002\/ibra.12126","journal-title":"Ibrain"},{"issue":"10284","key":"2341_CR187","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE et al (2021) Alzheimer\u2019s disease. Lancet 397(10284):1577\u20131590","journal-title":"Lancet"},{"issue":"13","key":"2341_CR188","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1002\/hbm.24517","volume":"42","author":"M Scherr","year":"2021","unstructured":"Scherr M, Utz L, Tahmasian M, Pasquini L, Grothe MJ, Rauschecker JP et al (2021) Effective connectivity in the default mode network is distinctively disrupted in Alzheimer\u2019s disease\u2014a simultaneous resting\u2010state FDG\u2010PET\/fMRI study. Hum Brain Mapp 42(13):4134\u20134143. https:\/\/doi.org\/10.1002\/hbm.24517","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"2341_CR189","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s43587-020-00008-0","volume":"1","author":"SE Schindler","year":"2021","unstructured":"Schindler SE, Bateman RJ (2021) Combining blood-based biomarkers to predict risk for Alzheimer\u2019s disease dementia. Nat Aging 1(1):26\u201328","journal-title":"Nat Aging"},{"issue":"3","key":"2341_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14030522","volume":"14","author":"TG Schreiner","year":"2026","unstructured":"Schreiner TG, Ciobanu RC, Schreiner OD (2026) Tau protein aggregation inhibitors\u2014therapeutic strategy for concurrent tau and amyloid aggregation inhibition. Biomedicines 14(3):522","journal-title":"Biomedicines"},{"issue":"3","key":"2341_CR191","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41588-020-00776-w","volume":"53","author":"J Schwartzentruber","year":"2021","unstructured":"Schwartzentruber J, Cooper S, Liu JZ, Barrio-Hernandez I, Bello E, Kumasaka N et al (2021) Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer\u2019s disease risk genes. Nat Genet 53(3):392\u2013402","journal-title":"Nat Genet"},{"issue":"10","key":"2341_CR192","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","volume":"16","author":"DR Serrano","year":"2024","unstructured":"Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G et al (2024) Artificial Intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics 16(10):1328","journal-title":"Pharmaceutics"},{"issue":"1","key":"2341_CR193","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20(1):68\u201380","journal-title":"Lancet Neurol"},{"issue":"1","key":"2341_CR194","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02249-z","volume":"22","author":"AM Shafik","year":"2021","unstructured":"Shafik AM, Zhang F, Guo Z, Dai Q, Pajdzik K, Li Y et al (2021) N6-methyladenosine dynamics in neurodevelopment and aging, and its potential role in Alzheimer\u2019s disease. Genome Biol 22(1):17. https:\/\/doi.org\/10.1186\/s13059-020-02249-z","journal-title":"Genome Biol"},{"issue":"4","key":"2341_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040742","volume":"10","author":"C Sharma","year":"2022","unstructured":"Sharma C, Woo H, Kim SR (2022) Addressing blood\u2013brain barrier impairment in Alzheimer\u2019s disease. Biomedicines 10(4):742","journal-title":"Biomedicines"},{"key":"2341_CR196","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2022.03.010","volume":"116","author":"B Shen","year":"2022","unstructured":"Shen B, Hernandez DG, Chitrala KN, Fanelli-Kuczmarski MT, Noren Hooten N, Pacheco NL et al (2022) APOE gene region methylation is associated with cognitive performance in middle-aged urban adults. Neurobiol Aging 116:41\u201348","journal-title":"Neurobiol Aging"},{"issue":"19","key":"2341_CR197","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/cells14191506","volume":"14","author":"X Shen","year":"2025","unstructured":"Shen X, Li H, Zhang B, Li Y, Zhu Z (2025) Tau-targeted therapeutic strategies: mechanistic targets, clinical pipelines, and analysis of failures. Cells 14(19):1506","journal-title":"Cells"},{"key":"2341_CR198","doi-asserted-by":"publisher","DOI":"10.1126\/science.adx0043","author":"FD Shi","year":"2025","unstructured":"Shi FD, Yong VW (2025) Neuroinflammation across neurological diseases. Science https:\/\/doi.org\/10.1126\/science.adx0043","journal-title":"Science (80)"},{"issue":"1","key":"2341_CR199","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11033-025-10297-6","volume":"52","author":"S Singh","year":"2025","unstructured":"Singh S, Singh RK (2025) Recent advancements in the understanding of the alterations in mitochondrial biogenesis in Alzheimer\u2019s disease. Mol Biol Rep 52(1):173. https:\/\/doi.org\/10.1007\/s11033-025-10297-6","journal-title":"Mol Biol Rep"},{"issue":"11","key":"2341_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/life13112156","volume":"13","author":"A Srivastava","year":"2023","unstructured":"Srivastava A, Johnson M, Renna HA, Sheehan KM, Ahmed S, Palaia T et al (2023) Therapeutic potential of P110 peptide: new insights into treatment of Alzheimer\u2019s disease. Life 13(11):2156","journal-title":"Life"},{"issue":"7","key":"2341_CR201","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/biom14070833","volume":"14","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhang X, So KF, Jiang W, Chiu K (2024) Targeting microglia in Alzheimer\u2019s disease: pathogenesis and potential therapeutic strategies. Biomolecules 14(7):833","journal-title":"Biomolecules"},{"issue":"3","key":"2341_CR202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5580","volume":"56","author":"Y Sun","year":"2025","unstructured":"Sun Y, Wei K, Liao X, Wang J, Gao L, Pang B (2025) Lipid metabolism in microglia: emerging mechanisms and therapeutic opportunities for neurodegenerative diseases (review). Int J Mol Med 56(3):1\u201319. https:\/\/doi.org\/10.3892\/ijmm.2025.5580","journal-title":"Int J Mol Med"},{"issue":"3","key":"2341_CR203","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2174\/1573413718666220627140824","volume":"19","author":"VS Tambe","year":"2023","unstructured":"Tambe VS, Wairkar S (2023) Lipid-based Nanocarriers via Nose-to-Brain Pathway for Alzheimer\u2019s and Parkinson\u2019s Disease. Curr Nanosci 19(3):322\u2013337","journal-title":"Curr Nanosci"},{"key":"2341_CR204","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12881","author":"JL Taylor","year":"2024","unstructured":"Taylor JL, Martin\u2010Aragon Baudel M, Nieves\u2010Cintron M, Navedo MF (2024) Vascular function and ion channels in Alzheimer\u2019s disease. Microcirculation. https:\/\/doi.org\/10.1111\/micc.12881","journal-title":"Microcirculation"},{"issue":"11","key":"2341_CR205","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.3390\/ijms23115938","volume":"23","author":"DM Teleanu","year":"2022","unstructured":"Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vlad\u00e2cenco O, Roza E et al (2022) An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci 23(11):5938","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2341_CR206","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21(1):66\u201377","journal-title":"Lancet Neurol"},{"issue":"1","key":"2341_CR207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46(1):1\u201317. https:\/\/doi.org\/10.1007\/s10753-022-01721-1","journal-title":"Inflammation"},{"issue":"4","key":"2341_CR208","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M et al (2020) Association of apolipoprotein E \u03b54 with medial temporal Tau independent of Amyloid-\u03b2. JAMA Neurol 77(4):470","journal-title":"JAMA Neurol"},{"issue":"3","key":"2341_CR209","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 26(3):387\u2013397","journal-title":"Nat Med"},{"key":"2341_CR210","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/B978-0-12-823384-9.00016-5","volume":"185","author":"DC Tippett","year":"2022","unstructured":"Tippett DC, Keser Z (2022) Clinical and neuroimaging characteristics of primary progressive aphasia. Handb Clin Neurol 185:81\u201397","journal-title":"Handb Clin Neurol"},{"key":"2341_CR211","doi-asserted-by":"publisher","unstructured":"Tirichen H, Yaigoub H, Xu W, Wu C, Li R, Li Y 2021 Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress. Front Physiol https:\/\/doi.org\/10.3389\/fphys.2021.627837\/full","DOI":"10.3389\/fphys.2021.627837\/full"},{"key":"2341_CR212","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.22.25338569","author":"AN Trelle","year":"2025","unstructured":"Trelle AN, Cody KA, Nguyen TT, Winer JR, Weiss S, Sai I et al (2025). Plasma Proteomic Signatures of Preclinical Alzheimer\u2019s Disease Biomarkers and Memory in Clinically Unimpaired Older Adults. https:\/\/doi.org\/10.1101\/2025.10.22.25338569","journal-title":"Plasma Proteomic Signatures of Preclinical Alzheimer\u2019s Disease Biomarkers and Memory in Clinically Unimpaired Older Adults"},{"issue":"1","key":"2341_CR213","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00826-3","volume":"13","author":"S Tsuji","year":"2021","unstructured":"Tsuji S, Hase T, Yachie-Kinoshita A, Nishino T, Ghosh S, Kikuchi M et al (2021) Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer\u2019s disease. Alzheimers Res Ther 13(1):92. https:\/\/doi.org\/10.1186\/s13195-021-00826-3","journal-title":"Alzheimers Res Ther"},{"key":"2341_CR214","doi-asserted-by":"crossref","unstructured":"Valgimigli L (2023) Lipid peroxidation and antioxidant protection. Biomolecules 13(9):1291","DOI":"10.3390\/biom13091291"},{"issue":"1","key":"2341_CR215","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"2341_CR216","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70886","author":"R Venkatesh","year":"2025","unstructured":"Venkatesh R, Cardone KM, Bradford Y, Moore AK, Kumar R, Moore JH et al (2025) Integrative multi\u2010omics approaches identify molecular pathways and improve Alzheimer\u2019s disease risk prediction. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.70886","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2341_CR217","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/life14020233","volume":"14","author":"AI Visan","year":"2024","unstructured":"Visan AI, Negut I (2024) Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life 14(2):233","journal-title":"Life"},{"issue":"1","key":"2341_CR218","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang W, Zhao F, Ma X, Perry G, Zhu X (2020) Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances. Mol Neurodegener 15(1):30. https:\/\/doi.org\/10.1186\/s13024-020-00376-6","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2341_CR219","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02452-x","volume":"22","author":"S Wang","year":"2022","unstructured":"Wang S, Lv W, Li T, Zhang S, Wang H, Li X et al (2022) Dynamic regulation and functions of mRNA m6A modification. Cancer Cell Int 22(1):48. https:\/\/doi.org\/10.1186\/s12935-022-02452-x","journal-title":"Cancer Cell Int"},{"key":"2341_CR220","doi-asserted-by":"publisher","first-page":"1117172","DOI":"10.3389\/fimmu.2023.1117172\/full","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, Zong S, Cui X, Wang X, Wu S, Wang L et al (2023) The effects of microglia-associated neuroinflammation on Alzheimer\u2019s disease. Front Immunol 14:1117172. https:\/\/doi.org\/10.3389\/fimmu.2023.1117172\/full","journal-title":"Front Immunol"},{"key":"2341_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122282","volume":"336","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liang J, Xu B, Yang J, Wu Z, Cheng L (2024) TrkB\/BDNF signaling pathway and its small molecular agonists in CNS injury. Life Sci 336:122282","journal-title":"Life Sci"},{"key":"2341_CR222","doi-asserted-by":"publisher","unstructured":"Wang K, Yang R, Li J, Wang H, Wan L, He J (2025) Nanocarrier-based targeted drug delivery for Alzheimer\u2019s disease: addressing neuroinflammation and enhancing clinical translation. Front Pharmacol 16. https:\/\/doi.org\/10.3389\/fphar.2025.1591438\/full","DOI":"10.3389\/fphar.2025.1591438\/full"},{"issue":"6","key":"2341_CR223","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40120-024-00664-z","volume":"13","author":"A Wicker","year":"2024","unstructured":"Wicker A, Shriram J, Decourt B, Sabbagh MN (2024) Passive anti-amyloid beta monoclonal antibodies: lessons learned over past 20 years. Neurol Ther 13(6):1571\u20131595. https:\/\/doi.org\/10.1007\/s40120-024-00664-z","journal-title":"Neurol Ther"},{"issue":"2","key":"2341_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics16020196","volume":"16","author":"CJ Wiedermann","year":"2026","unstructured":"Wiedermann CJ, Piccoliori G, Engl A, Hager von Strobele-Prainsack D (2026) Predictive biomarkers for asymptomatic adults: opportunities, risks, and guidance for general practice. Diagnostics (Basel) 16(2):196","journal-title":"Diagnostics (Basel)"},{"key":"2341_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102176","volume":"61","author":"B Wilson","year":"2021","unstructured":"Wilson B, Mohamed Alobaid BN, Geetha KM, Jenita JL (2021) Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat Alzheimer\u2019s disease. J Drug Deliv Sci Technol 61:102176","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"2341_CR226","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/pharmaceutics14040836","volume":"14","author":"BA Witika","year":"2022","unstructured":"Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, MalungeloKhamanga SM et al (2022) Lipid-based nanocarriers for neurological disorders: a review of the state-of-the-art and therapeutic success to date. Pharmaceutics 14(4):836","journal-title":"Pharmaceutics"},{"key":"2341_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101202","volume":"65","author":"AG Wu","year":"2021","unstructured":"Wu AG, Zhou XG, Qiao G, Yu L, Tang Y, Yan L et al (2021) Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. Ageing Res Rev 65:101202","journal-title":"Ageing Res Rev"},{"key":"2341_CR228","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq6038","author":"X Wu","year":"2025","unstructured":"Wu X, Miller JA, Lee BTK, Wang Y, Ruedl C (2025) Reducing microglial lipid load enhances \u03b2 amyloid phagocytosis in an Alzheimer\u2019s disease mouse model. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.adq6038","journal-title":"Sci Adv"},{"issue":"1","key":"2341_CR229","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01571-z","volume":"16","author":"A Wuestefeld","year":"2024","unstructured":"Wuestefeld A, Pichet Binette A, van Westen D, Strandberg O, Stomrud E, Mattsson-Carlgren N et al (2024) Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer\u2019s disease. Alzheimers Res Ther 16(1):204. https:\/\/doi.org\/10.1186\/s13195-024-01571-z","journal-title":"Alzheimers Res Ther"},{"key":"2341_CR230","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jconrel.2023.11.018","volume":"365","author":"S Xie","year":"2024","unstructured":"Xie S, Wei L, Liu Y, Meng J, Cao W, Qiu B et al (2024) Size-tunable nanogels for cascaded release of metronidazole and chemotherapeutic agents to combat Fusobacterium nucleatum-infected colorectal cancer. J Control Release 365:16\u201328","journal-title":"J Control Release"},{"key":"2341_CR231","doi-asserted-by":"publisher","unstructured":"Xu MR, Dai RF, Wei QQ, Wang J, Feng YY, Hu Y 2022 Urinary AD7c-NTP evaluates cognition impairment and differentially diagnoses AD and MCI. Am J Alzheimer\u2019s Dis Other Dementias\u00ae. https:\/\/doi.org\/10.1177\/15333175221115247","DOI":"10.1177\/15333175221115247"},{"issue":"8","key":"2341_CR232","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tem.2023.05.002","volume":"34","author":"LG Yang","year":"2023","unstructured":"Yang LG, March ZM, Stephenson RA, Narayan PS (2023) Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol Metab 34(8):430\u2013445","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"2341_CR233","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70645","volume":"21","author":"AJT Yang","year":"2025","unstructured":"Yang AJT, Mohammad A, Crozier RWE, Maddalena L, Tsiani E, MacNeil AJ et al (2025) Differences in inflammatory markers, mitochondrial function, and synaptic proteins in male and female Alzheimer\u2019s disease post mortem brains. Alzheimer\u2019s Dement 21(10):e70645. https:\/\/doi.org\/10.1002\/alz.70645","journal-title":"Alzheimer\u2019s Dement"},{"key":"2341_CR234","doi-asserted-by":"publisher","unstructured":"Yang X, Yang W, Xia X, Lei T, Yang Z, Jia W, et al (2022) Intranasal Delivery of BACE1 siRNA and Rapamycin by Dual Targets Modified Nanoparticles for Alzheimer\u2019s Disease Therapy. Small https:\/\/doi.org\/10.1002\/smll.202203182","DOI":"10.1002\/smll.202203182"},{"issue":"1","key":"2341_CR235","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","volume":"9","author":"J Yao","year":"2024","unstructured":"Yao J, Sterling K, Wang Z, Zhang Y, Song W (2024) The role of inflammasomes in human diseases and their potential as therapeutic targets. Signal Transduct Target Ther 9(1):10","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2341_CR236","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/brain\/awab120","volume":"144","author":"SY Yap","year":"2021","unstructured":"Yap SY, Frias B, Wren MC, Sch\u00f6ll M, Fox NC, \u00c5rstad E et al (2021) Discriminatory ability of next-generation tau PET tracers for Alzheimer\u2019s disease. Brain 144(8):2284\u20132290","journal-title":"Brain"},{"key":"2341_CR237","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00679","author":"SJ Yong","year":"2023","unstructured":"Yong SJ, Veerakumarasivam A, Lim WL, Chew J (2023) Neuroprotective effects of lactoferrin in Alzheimer\u2019s and Parkinson\u2019s diseases: a narrative review. ACS Chem Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.2c00679","journal-title":"ACS Chem Neurosci"},{"key":"2341_CR238","doi-asserted-by":"publisher","first-page":"23","DOI":"10.36255\/exonpublications.alzheimersdisease.2020.ch2","volume-title":"Alzheimer\u2019s disease: drug discovery","author":"S Zampar","year":"2020","unstructured":"Zampar S, Wirths O (2020) Immunotherapy targeting amyloid-\u00df peptides in Alzheimer\u2019s disease. Alzheimer\u2019s disease: drug discovery. Exon Publications, pp 23\u201349"},{"issue":"8","key":"2341_CR239","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40629-024-00312-w","volume":"33","author":"H Zander","year":"2024","unstructured":"Zander H, Engelbergs J (2024) Requirements for regulatory acceptance of biomarkers. Allergo J Int 33(8):309\u2013312. https:\/\/doi.org\/10.1007\/s40629-024-00312-w","journal-title":"Allergo J Int"},{"issue":"1","key":"2341_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00430-x","volume":"16","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K (2021) Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics. Mol Neurodegener 16(1):10. https:\/\/doi.org\/10.1186\/s13024-021-00430-x","journal-title":"Mol Neurodegener"},{"issue":"2","key":"2341_CR241","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/cbdd.14248","volume":"102","author":"J Zhang","year":"2023","unstructured":"Zhang J, Li C, Zhang Y, Wu J, Huang Z (2023) Therapeutic potential of nitric oxide in vascular aging due to the promotion of angiogenesis. Chem Biol Drug des 102(2):395\u2013407. https:\/\/doi.org\/10.1111\/cbdd.14248","journal-title":"Chem Biol Drug des"},{"issue":"1","key":"2341_CR242","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-024-00429-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang J, Zhang Z, Ye K (2024) Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener 13(1):40. https:\/\/doi.org\/10.1186\/s40035-024-00429-6","journal-title":"Transl Neurodegener"},{"issue":"10","key":"2341_CR243","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/brainsci15101101","volume":"15","author":"B Zhang","year":"2025","unstructured":"Zhang B, Li Y, Li H, Shen X, Zhu Z (2025) Therapeutic advances in targeting the amyloid-\u03b2 pathway for Alzheimer\u2019s disease. Brain Sci 15(10):1101","journal-title":"Brain Sci"},{"issue":"2","key":"2341_CR245","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X (2025) Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell 16(2):83\u2013120","journal-title":"Protein Cell"},{"issue":"8","key":"2341_CR246","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1007\/s12035-025-04838-0","volume":"62","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, Wang W, Deng C (2025) Advancements in proteolysis targeting chimeras for targeted therapeutic strategies in Alzheimer\u2019s disease. Mol Neurobiol 62(8):9686\u20139709. https:\/\/doi.org\/10.1007\/s12035-025-04838-0","journal-title":"Mol Neurobiol"},{"issue":"16","key":"2341_CR247","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Venkatesh DN et al (2020) Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules 25(16):3731","journal-title":"Molecules"},{"issue":"18","key":"2341_CR248","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107100","volume":"40","author":"S Zocher","year":"2021","unstructured":"Zocher S, Overall RW, Berdugo\u2010Vega G, Rund N, Karasinsky A, Adusumilli VS et al (2021) De novo DNA methylation controls neuronal maturation during adult hippocampal neurogenesis. EMBO J 40(18):EMBJ2020107100. https:\/\/doi.org\/10.15252\/embj.2020107100","journal-title":"EMBO J"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02341-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02341-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02341-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:03:17Z","timestamp":1788966197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02341-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":246,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2341"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02341-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies involving human participants or animals performed by any of the authors. Therefore, ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":4,"name":"Ethics","label":"Clinical trial","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that this manuscript is original, has not been published previously, and is not under consideration for publication elsewhere. The work adheres to ethical guidelines of scientific publishing, and all sources have been appropriately cited.","order":6,"name":"Ethics","label":"Plagiarism and publication ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that AI assisted tools were used solely for language refinement, grammar correction, and improvement of clarity and readability of the manuscript. The AI tools did not generate scientific content, interpret data, perform analyses, or influence the study design, results, or conclusions. All intellectual content, data interpretation, and scientific responsibility remain entirely with the authors.","order":7,"name":"Ethics","label":"Use of artificial intelligence (AI) tools","group":{"name":"EthicsHeading","label":"Declarations"}}]}}